| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8790368 | Urologic Oncology: Seminars and Original Investigations | 2017 | 6 Pages |
Abstract
CDRCC is an aggressive subtype of renal cell carcinoma. Median survival is 13 months after diagnosis, drastically lower than for CCRCC. More than 70% of patients have metastatic disease at diagnosis. Chemo/radiation in addition to CNx is associated with a survival benefit over single mode therapy.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Wilson B.A., Justin T. M.D., Dennis J. M.D., Maxwell B. B.A., Ifeanyi C. B.A., Arindam Ph.D., Sven M.D., Guarionex Joel M.D.,